The expression of the c-erbB-1, c-myc, Ha/N-ras and c-fos oncogenes was investigated in 62 astrocytomas of low, intermediate and high grades by immunogold silver histochemistry. Elevated expression of c-erbB-l was observed in 95%, 48% and 86% of low, intermediate and high grade tumours respectively, c-myc in 5%, 33% and 76% respectively, Ha/N-ras in 0, 43% and 71% respectively and c-fos in 55%, 48% and 52% respectively. Controls included normal brain and tumour sections immunoreacted with pre-immune serum or with antisera absorbed with synthetic peptides. Analysis of co-overexpression revealed that low grade tumours co-overexpressed a maximum of two of these genes, intermediate grade tumours a maximum of three of these genes, while co-overexpression of all four genes was observed in some high grade tumours. Co-overexpression of c-erbB-1 and c-fos was frequently observed in low grade astrocytomas and may be predictive of non-progression. On the other hand, there was a statistically significant increase in the number of tumours overexpressing Ha/N-ras or c-myc with increasing grade of tumour, suggesting that overexpression of these two oncogenes may be indicative of progression.
Summary
The expression of the c-erbB-1, c-myc, Ha/N-ras and c-fos oncogenes was investigated in 62 astrocytomas of low, intermediate and high grades by immunogold silver histochemistry. Elevated expression of c-erbB-l was observed in 95%, 48% and 86% of low, intermediate and high grade tumours respectively, c-myc in 5%, 33% and 76% respectively, Ha/N-ras in 0, 43% and 71% respectively and c-fos in 55%, 48% and 52% respectively. Controls included normal brain and tumour sections immunoreacted with pre-immune serum or with antisera absorbed with synthetic peptides. Analysis of co-overexpression revealed that low grade tumours co-overexpressed a maximum of two of these genes, intermediate grade tumours a maximum of three of these genes, while co-overexpression of all four genes was observed in some high grade tumours. Co-overexpression of c-erbB-1 and c-fos was frequently observed in low grade astrocytomas and may be predictive of non-progression. On the other hand, there was a statistically significant increase in the number of tumours overexpressing Ha/N-ras or c-myc with increasing grade of tumour, suggesting that overexpression of these two oncogenes may be indicative of progression.
Gliomas are tumours of non-neuronal, supporting cells of the brain. They may be of astrocytic, oligodendroglial or ependymal lineage and mixed gliomas may also occur (Zulch, 1986) . Astrocytomas are the commonest of the glial tumours and comprise over 45% of childhood (Becker & Yates, 1986) and 50% of adult primary brain tumours (Zulch, 1986) .
There is considerable variation in the behaviour of astrocytomas. Some remain as indolent low grade tumours while others are believed to progress to higher grades of malignancy. Determination of the likelihood of progression presently relies heavily on histological criteria. Appraisal of the potential for progression would be greatly enhanced by the availability of biological markers, especially if these could be quantitated.
Oncogenes have been shown to act as useful markers of progression in some human tumours. Studies of over 800 patients with neuroblastoma (Bertram & Berthold, 1987; Nakagarawa et al., 1987; Tsuda et al., 1987 , and see Brodeur, 1990 for review), a tumour of primitive neuronal cells which occurs predominantly outside the brain, have shown that amplification of the N-myc oncogene is associated with rapid progression and poor prognosis. Another oncogene which may serve as a marker of prognosis is c-erbB-2 (or HER-2 or neu). Initial studies correlated c-erbB-2 amplification in breast carcinoma with poorer prognosis (Slamon et al., 1987) . However these findings have been disputed due to the considerable variation in other clinical parameters (for review see Maguire & Green, 1989) . Recent data, however, indicate that c-erbB-2 amplification may be an indicator of behaviour of the comedo subtype of breast carcinoma (Van de Vijver et al., 1988; Borg et al., 1989) .
Activation of a number of oncogenes has been reported in astrocytomas but to date, none of these has been shown to be associated with progression. The best characterised is the c-erbB-1 oncogene which encodes the epidermal growth factor receptor (EGF-R) (Dalla-Favera & Cesarman, 1986 (Liberman et al., 1985; Malden et al., 1988; Wong et al., 1987) . Elevated levels of c-erbB-l mRNA occurred independently of amplification in 17 of 19 (89%) gliomas in one study (Malden et al., 1988) . Activation, characterised by elevated mRNA levels, of c-myc (Englehard et al., 1989; Trent et al., 1986) , N-myc (Garson et al., 1985; Kinzler et al., 1986; Fujimoto et al., 1989) , N-ras (Gerosa et al., 1988) and gli has also been reported in glial tumours.
The above data were derived from primary tumours. Studies of astrocytoma-derived cell lines have demonstrated a different profile of oncogene activation e.g. c-abl, c-sis, c-ros and c-raf (Blin et al., 1987; Henn et al., 1986; Fukui et al., 1987; Wu & Chikaraishi, 1990) . These studies suggest that examination of biopsy-derived material from primary astrocytic tumours is more appropriate than cell lines to investigate the in vivo activation of oncogenes.
In this study we have investigated the overexpression of four oncogenes in 62 astrocytic tumours of differing grades to determine whether there is an association between the profile of expression and tumour grade. It is not possible to study the same tumour in vivo at different time points and we believe this to be the most appropriate method of determining an association between oncogene activity and progression. The oncogenes investigated were c-erbB-l the product of which (EGF-R) is a membrane associated tyrosine kinase receptor, c-myc and c-fos the products of which are postulated to have DNA binding activity, and ras which encodes a G-binding protein active on the inner side of the cytoplasmic membrane (Dalla-Favera & Cesarman, 1986 ). An association between activation of c-erbB-1 and c-myc and N-ras in astrocytomas has been established, while that of c-fos has not previously been reported. These oncogenes were selected in this study to determine if a pattern of co-activation of cellmembrane-associated, cytoplasmic and nuclear oncogenes could be observed in different tumour grades. Our data show that overexpression of c-erbB-1, or c-fos is probably not useful in predicting biological behaviour, while that of c-myc or Ha/N-ras may be. In addition it is also shown that co-overexpression of up to four oncogenes is most common in high grade astrocytomas.
Materials and methods

Materials
Monoclonal antibodies against the products of the c-erbB-l and c-myc oncogenes and polyclonal antisera (raised in sheep) against the c-fos and ras oncogene products were purchased from Cambridge Research Biochemicals (Gadbrook Park, Norwich UK). The antibody against the c-erbB-1 gene product was raised against a 12-residue peptide derived from the extracellular domain of the EGF-R protein sequence, that against the c-myc gene product was raised against a 31-residue peptide from human c-myc and that against the c-fos gene product was raised against an 11-residue peptide from human c-fos. The ras antiserum was raised against an N-terminal 18-residue peptide common to all proteins. However this antibody was tested using cell lines overexpressing N-ras or Ha-ras only. Since the ability of the antibody to detect Ki-ras is unproven, we have not assumed that Ki-ras was also present and tumours showing positive immunoreactivity are described as positive for Ha/N-ras. Also none of the above antisera distinguish between wildtype and mutated gene products. The specificity of each of these antibody preparations has been demonstrated (Yeaton et al., 1983; Lacal & Tronick, 1988; Evan & Hancock, 1985) . Secondary antisera (gold-conjugated goat-anti-mouse and goat-anti-rabbit IgG) were purchased from Sigma (St. Louis Mo. USA) and a linking antiserum (rabbit-anti-sheep IgG) from Dakopatts (Glostrup, Denmark). Synthetic peptides for EGF-R, c-myc, HaIN-ras and c-fos were obtained from Cambridge Research Biochemicals. Silver nitrate and hydroquinone (1,4 benzenediol) were purchased from Sigma.
Tissue
Sixty-two astrocytomas comprising 20 low grade (juvenile pilocytic astrocytomas) (Zulch, 1986) , 21 intermediate grade tumours (anaplastic astrocytomas) and 21 high grade tumours (glioblastoma multiforme) (Ringertz, 1950) , and eight cases of normal brain and/or brain adjacent to tumour were used in this study. Cases of high and intermediate grade tumours and normal brain and brain adjacent to tumour were selected sequentially from archival material in the Department of Anatomical Pathology, Royal Melbourne Hospital and low grade tumours from archival material in the Department of Anatomical Pathology, Royal Children's Hospital, Melbourne. All samples had been initially derived from surgical biopsies or resections. Samples from both hospitals were fixed in 10% formalin and processed in an identical manner. The original Haematoxylin and Eosin (H&E)-stained paraffin sections were reviewed and tumours graded according to the Ringertz criteria (Ringertz, 1950) .
Immunogold silver staining (IGSS)
The techique used was adapted from Holgate et al. (1983) . Briefly 6 JL sections were dewaxed in xylene, rehydrated in graded alcohols, immersed in Lugol's Iodine for 5 min and decolourised in 2.5% sodium thiosulphate. After equilibration in Tris-buffered saline, pH 7.4 (TBS) sections were blocked with 10% normal swine serum or newborn calf serum in TBS for 15 min at room temperature in a moist chamber. Sections were then incubated with the primary antibody at the appropriate dilution in TBS containing 10% serum for 1 to 2 h at room temperature or 4 to 16 h at 4°C. For monoclonal antibodies, sections were washed briefly in TBS and incubated with a goat-anti-mouse IgG/gold conjugate at a dilution of 1 in 50 in TBS containing 10% serum for 1 to 2 h at room temperature or 4 to 16 h at 4°C.
Sections were then sequentially washed in TBS and distilled water and incubated for 3 min in physical development solution in the dark. Sections were then fixed in 5% sodium thiosulphate for 3 min and rinsed in distilled water. They were then counterstained in Nuclear Fast Red B, dehydrated in graded alcohols, cleared in xylene, mounted and examined by light microscopy.
Sections immunoreacted with polyclonal antisera were rinsed briefly in TBS following incubation with the primary antiserum and then incubated with a rabbit-anti-sheep IgG linking antiserum for 1 h at room temperature. Sections were then incubated with a goat-anti-rabbit IgG/gold conjugate and processed exactly as described for monoclonal antibodies.
Negative controls included (a) sections immunoreacted in the absence of primary antibody and (b) sections immunoreacted with antibody preparations which had been absorbed with the oncoprotein synthetic peptides as follows. Each of the synthetic peptides was conjugated to Sepharose beads (Harlow & Lane, 1988) and each preparation of conjugated peptide was then incubated with the corresponding antibody preparation for 1 h at room temperature. The beads were then removed by centrifugation and the supernatant collected. The supernatant was then used as described above for the primary antibody.
Immunoreactivity was assessed by light microscopy as a greater density of silver grains over nuclei or over the cytoplasmic compartment of cells in tumour sections (Figure 1 ) compared with negative controls. In both types of negative controls, the grain density averaged 10 per x 1000 field. Immunoreactivity was regarded as positive if the grain density was 10 or more per individual cell. Although the IGSS technique can be used to semi-quantify oncoprotein levels by grain counting, we did not attempt quantitation in this study and only assessed whether overexpression of each oncogene was occurring in each tumour. The product of any one oncogene was regarded as being overexpressed if immunoreactivity could be detected in tumour sections at dilutions higher than in sections of normal white matter. To determine these dilutions, sections from eight randomly selected samples of normal white matter and/or brain adjacent to tumour zone were immunoreacted with serially diluted antibody preparations. Immunoreactivity in normal white matter for EGF-R became undetectable at a dilution of 1 in 400 and cut-off dilutions for c-myc, HaIN-ras and c-fos were 1 in 500, 1 in 700 and 1 in 1,800 respectively. The same antibody preparations were used throughout the study.
Statistical analysis of data Statistically significant differences in the occurrence of overexpression of each oncogene and co-overexpression of two, three or four oncogenes between each of the three tumour groups were determined by 95% confidence intervals (95% CI), Fisher's exact test and test for trend in proportion (Armitage & Berry, 1987) .
Results
Pattern of overexpression of oncogenes in astrocytic tumours
The data are summarised in Table I No pattern of c-erbB-1 overexpression was observed across the different grades of astrocytoma. Elevated expression of c-erbB-1 was observed in 19/20 (95%) and 18/21 (86%) of low grade tumours and glioblastoma multiforme respectively, but in only 10/21 (48%) of anaplastic astrocytomas. There was a significant difference in the percent of tumours with overexpression of this oncogene between low grade tumours and anaplastic astrocytomas (95% CI; 23,71) and between anaplastic astrocytomas and glioblastoma multiforme (95% CI; 11,65). However, because of the occurrence of overexpression of this oncogene in the majority of all grades of astrocytomas, it would appear that activation of c-erbB-1 alone is not an indicator of progression. Overexpression of the c-fos oncogene occurs in approximately equal numbers of low grade tumours (11/20; 55%), anaplastic astrocytomas (10/21; 48%) and glioblastoma multiforme (11/21; 52%), and no significant differences were observed between any of the groups. This suggests that, similar to the c-erbB-1 oncogene, overexpression of the c-fos oncogene alone is not an indicator of progression. Figure 1 Elevated expression of the c-erbB-1, c-myc, Ha/N-ras and c-fos gene products in astrocytomas. Sections were immunoreacted with antibodies against EGF-R (diluted 1 in 400), c-myc (diluted 1 in 500), Ha/N-ras (diluted 1 in 700) and c-fos (diluted 1 in 1,800), then incubated with a gold-labelled second antibody. Following incubation in physical development solution sections were counterstained with Nuclear Fast Red B. a, glioblastoma multiforme immunoreacted with anti-EGF-R, x 1000; b, glioblastoma multiforme immunoreacted with anti-c-myc, ). JQ00; (.c) anaplastic astrocytoma immunoreacted with anti-Ha/Nras, x 1000; d, anaplastic astrocytoma immunoreacted with anti-c-fos, x 1000; e, anaplastic astrocytoma shown in c, in the absence of primary antibody, x 400; f, normal brain immunoreacted with anti-EGF-R (diluted 1 in 100) which had been absorbed with EGF-R peptide, x 400. Identical results were obtained when normal brain was immunoreacted with antibodies absorbed with the c-myc, Ha/N-ras and c-fos peptides. Positive immunoreactivity was detected-as the presence of silver gr-ains; Silver grains were concentrated predominantly outside nuclei in sections immunoreacted with anti-EGF-R and anti-Ha/N-ras antibodies and predominantly over nuclei in sections immunoreacted with anti-c-myc antibody. In the case of sections immunoreacted with anti-c-fos antibody, silver grains appeared to be concentrated predominantly over nuclei, but significant cytoplasmic immunoreactivity was also observed. This is in agreement with previous studies which have shown a similar pattern of subcellular localisation of the fos product (Curran et al., 1984; Curran et al., 1985) .
Ha/N-ras overexpression was not observed in any of the low grade astrocytomas, but was present in 9/21 (43%) of anaplastic astrocytomas and 15/21 (71%) glioblastoma multiforme. Because no low grade tumours were found to overexpress Ha/N-ras, a confidence interval test to determine the significance or otherwise of the difference between low grade tumours and anaplastic astrocytomas could not be performed. There was no significant difference in Ha/N-ras overexpression between anaplastic astrocytomas and glioblastoma multiforme (-0.9,58). However, to determine whether there was a statistically significant increase in the percent of tumours with Ha/N-ras overexpression across the Table II ).
three tumour grades, the test for trend in proportions was performed and the result was found to be highly significant (P<0.001). This suggests that the occurrence of Ha/N-ras overexpression increases with the grade of the tumour. Overexpression of c-myc occurred in 1/20 (5%) of low grade tumours, 7/21 (33%) of anaplastic astrocytomas and 16/21 (76%) of glioblastoma multiforme. There was a significant difference between the number of low grade tumours and anaplastic astrocytomas (95% CI; 5,51) and the number of anaplastic astrocytomas and glioblastoma multiforme (95% CI; 15,71) overexpressing this oncogene. The test for trend in proportions also showed that the increase in percent of tumours overexpressing c-myc across the three tumour grades was highly significant (P<0.001). This suggests that overexpression of c-myc similar to that of Ha/N-ras, may be an indicator of progression.
Oncogene co-expression in glial tumours
The pattern of co-overexpression of oncogenes in each grade of tumour is shown in Table II . It appears that the number of oncogenes co-overexpressed in the different grades of astrocytoma increases with the grade of tumour. Low grade tumours (12/20) co-overexpressed a maximum of two of the oncogenes under investigation, anaplastic astrocytomas a maximum of three of these oncogenes (4/21) and cooverexpression of all four oncogenes was observed in a number of glioblastoma multiforme (4/21). Co-overexpression of two oncogenes No significant difference was observed in co-overexpression of only two oncogenes in the three tumour groups (P<0.1). The combination of cerbB-l/c-fos (11/20) was frequently observed in low grade astrocytomas (11 cases). It was not observed in anaplastic astrocytomas and was found in a single case of glioblastoma multiforme. This suggests that the most likely grade of a tumour co-overexpressing only this combination of oncogenes is low grade. Co-overexpression of three oncogenes To determine statistically significant differences in co-overexpression -of three oncogenes between low grade tumours, anaplastic astrocytomas and glioblastoma multiforme the total number of cases co-overexpressing three oncogenes in each group was used (i.e. zero cases of low grade tumours, four cases of anaplastic astrocytomas and 11 cases of glioblastoma multiforme; see Table II ). Using chi-square analysis, a statistically significant difference was observed between anaplastic astrocytomas and glioblastoma multiforme (P<0.001). No preferred combination of oncogenes was observed. However, the combination of c-erbB-l1/c-myc/Ha/N-ras was most frequently observed in glioblastoma multiforme, while the combination c-erbB-1/Ha/N-ras/c-fos was most frequently observed in anaplastic astrocytomas. Co-overexpression offour oncogenes No cases of low grade tumours or anaplastic astrocytomas were found to cooverexpress four oncogenes. However four out of 21 glioblastoma multiforme were found to overexpress the four oncogenes under investigation. Using a Fisher's exact test a significant difference (P<0.03) was observed in the co- Table II Co-overexpression of oncogene products was calculated. For each grade of tumour, the number of samples expressing a maximum of two, or three or four oncogene products is shown. Each of the combinations shown is mutually exclusive. Each of the possible combinations were sought and a zero incidence appears for those combinations that were not observed. overexpression of four oncogenes across the three tumour grades.
Heterogeneity in staining pattern A number of tissues showed heterogeneity in the staining pattern in which the silver grains were not evenly distributed over the whole of the tumour. This was most noticeable in anaplastic astrocytomas immunoreacted with anti-EGF-R and is illustrated in Figure 2 . This observation suggests that there may be some clones within the tumour at any one time point in which genetic alterations are proceeding along different pathways in different regions of the tumour.
Discussion
In contrast to previous studies which concentrated predominantly on the activation of single oncogenes in glioblastomas, this study has investigated the activation of a number of oncogenes in low, intermediate and high grade astrocytomas. The study was designed in this way to determine if a particular pattern of oncogene co-overexpression is associated with histological grade. An immunohistological technique was used to determine over-expression because the study was performed on archival material, and because this technique allows visualisation of expression in individual tumour cells and of variation in expression in different regions of the same tumour. None of these aspects is possible with DNA and RNA blotting analyses and the latter techniques also do not allow correction for the increased cellularity of tumours. We observed elevated expression of c-erbB-1 in all grades of astrocytomas. The percentage of tumours showing elevated expression of c-erbB-1 in low grade astrocytomas was 95%. Elevated expression of this oncogene in low grade astrocytomas has previously been demonstrated in only 9% of cases by Reifenberger et al. (1989) . However their study included a number of low grade non-glial tumours in addition to low grade astrocytomas and the immunohistochemical technique used (peroxidase-anti-peroxidase) was different. Our data show that overexpression of c-erbB-l in low grade astrocytomas is much higher than previously appreciated. We also observed elevated expression of c-erbB-l in 86% of glioblastomas multiforme. This is comparable to data obtained by Reifenberger et al. (1989) who showed elevated expression in 79% of high grade astrocytomas by immunohistochemical techniques and data obtained by Malden et al. (1988) The percentage of tumours overexpressing c-erbB-1 was lower in anaplastic astrocytomas (48%) than in low grade tumours (95%) and glioblastoma multiforme (86%) ( Table  I ). The reason for this observation is not clear, but may be related to the occurrence of different types of mutations in this oncogene in the different grades of tumours. It is well documented that the c-erbB-l gene often undergoes extensive amplification and rearrangement in glioblastoma multiforme as a result of which the extracellular portion of the molecule is deleted (Liberman et al., 1985; Malden et al., 1988; Wong et al., 1987) . The anti-EGF-R monoclonal antibody used is directed against the extracellular portion of the molecule. One interpretation of our data would therefore be that cerbB-1 overexpression occurs in all gliomas but rearrangement of the gene resulting in the truncation of the EGF-R molecule is more common in anaplastic astrocytomas than in glioblastoma multiforme.
Elevated expression of the c-myc oncogene has been reported in isolated glial tumours (Englehard et al., 1989; Trent et al., 1986) , and there is a single report of elevated expression of N-ras in five glioblastomas (Gerosa et al., 1988) . Our data show that elevated expression of both c-myc and Ha/N-ras is a common feature of anaplastic astrocytomas and glioblastoma multiforme. Elevated expression of c-fos in astrocytomas has not been reported to our knowledge. Our data show that overexpression of this oncogene occurs in approximately 50% of all grades of astrocytoma.
A study aimed at identifying markers of tumour progression would ideally require the analysis of serial samples from the same set of patients. However ethical and practical considerations make this approach impossible in the case of astrocytic tumours.. It is therefore necessary to draw conclusions from a cross-sectional study. A statistically significant difference in overexpression of c-erbB-1 was found between low grade tumours, anaplastic astrocytomas and glioblastoma multiforme. However, we are not able to conclude that overexpression of c-erbB-1 is associated with progression since 95% of low grade tumours showed overexpression of this oncogene. The low grade astrocytomas in this study were of the juvenile pilocytic type in which progression occurs very rarely (Wallner et al., 1988) . It is to be noted that in a study of EGF-R activity in intracranial tumours, Hawkings et al. (1991) also concluded that EGF-R was of little prognostic significance. Overexpression of c-fos was found in approximately equal numbers of low grade tumours, anaplastic astrocytomas and glioblastoma multiforme and similarly does not appear to be significantly associated with any one grade of astrocytoma or with progression. An interesting finding was that 11 of 20 low grade tumours overexpressed the combination of c-erbBl and c-fos. This combination was not observed in anaplastic astrocytomas and was found in only one glioblastoma multiforme. This suggests that tumours found to be expressing the combination c-erbB-1/c-fos are more likely to be low grade and that they are unlikely to progress. On the other hand the proportion of samples overexpressing c-myc or Ha/N-ras increased with tumour grade. A test for trend in proportions, which is the more accurate statistical method to determine the significance of the increase observed across the three tumour grades showed this increase to be highly significant in each case, which strongly suggests that these two oncogenes are good candidates as markers of progression. Expression of the c-myc oncogene, has been shown to be related to the cell cycle. During the GO phase there is a low level of c-myc expression. When cells are stimulated to divide, endogenous c-myc levels increase as cells progress from the GO to the G1 and S phases of the cell cycle (Cole, 1986) . Enhanced expression of c-myc in astrocytic tumours may simply be an indication that a higher proportion of cells are in a proliferative phase compared with normal brain, but detection of this at any one time point may be an important indication of the likelihood of tumour progression.
Despite the relatively small number of tumours examined, our data strongly suggest that there is an increase in the number of oncogenes overexpressed concurrent with an increase in the severity of the tumour. Glioblastoma multiforme overexpressed more oncogenes than anaplastic and low grade astroctyomas. The current hypothesis regarding the molecular basis of tumour progression implies that oncoproteins act at all levels of signal transduction and that their deregulated expression drives cell proliferation (Hunter, 1991) . Recent evidence strongly suggests that sequential inactivation of oncogenes occurs hand-in-hand with loss of putative tumour suppressor genes (Marshall, 1991) and that both phenomena contribute to tumour initiation and progression. It is possible that overexpression of at least some of the four oncogenes in our study is a consequence of chromosomal aberrations and that their gene products may not work in collaboration to generate the tumour phenotype. On the other hand our data is in agreement with observations that mutational events do not have to occur in a particular sequence to promote tumour progression (Hunter, 1991) and that it is the total accumulation of mutations which is the crucial factor in determining progression to malignancy.
